NEWS BRIEFS

Cleveland, OHIO — Secant Technologies, Inc. announced that, after an extensive technology evaluation, Incyte Genomics, Inc., a leading genomic information company, has selected Secant’s Extreme Enterprise Server as a major element of its new Genomic Knowledge Platform, a unified software environment for bioinformatics research. Secant’s award-winning infrastructure software was selected as the foundation to rapidly develop, deploy and deliver Incyte’s unique human gene information to academic, biotechnology and pharmaceutical researchers around the world.

Secant’s application server technology is well suited for life sciences. Secant has tightly integrated its code generation technology with object modeling tools to dramatically reduce the time-to-market of large scale, database intensive applications. In addition, intelligent clustering, transaction, and data management services provide the vast scalability, performance, and fault tolerance required by systems like the Genomic Knowledge Platform.

Incyte and Secant are combining advances in science with advances in enterprise computing to revolutionize the way in which scientists conduct research and share information. “Secant’s technologies have been key to the success of our new Genomic Knowledge Platform enabling us to efficiently map complex biological models to our multiple genomic information sets,” said Roy Whitfield, Incyte’s chief executive officer.

“To provide tools powerful enough to study the breadth of human gene information, we needed an infrastructure to support a complex object model, vast scalability and extensive object-to-relational data management. When we evaluated the leading application servers, we found that Secant’s technologies were more advanced than everything else we considered,” said Lee Grover, vice president of software development of Incyte Genomics. “With Secant’s technology, we feel confident our applications can be deployed and managed on the broad scale we require.”

Secant has received numerous industry awards including Network Computing’s 2000 Well-Connected Award for Best Java Application Server, Oracle’s 1999 Top 50 List of e-Business Solution Providers, and a 1999 Editor’s Choice Award from Java Developer’s Journal. “Our technology has been generating a lot of excitement in the marketplace by winning a string of industry awards,” states Jim Holt, president of Secant. “But, we consider having customers like Incyte that base their key enterprise initiatives on our technology as our most significant award.” About Incyte

Incyte Pharmaceuticals, Inc. (doing business as Incyte Genomics, Inc.) is a leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, genomic data management software, microarray-based gene expression services, related reagents and services. These products, programs and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte’s web site at http://www.incyte.com .

Secant Technologies, Inc. is a leading provider of high-performance application server technology for building, deploying, hosting and managing the most demanding e-Business applications. With an emphasis on object-oriented and Internet technologies, Secant provides a complete platform for enterprise-caliber technology based on open standards. Organizations that have recognized business benefits from the use of Secant’s products include Incyte Genomics, XOL.com, Lockheed-Martin, Siemens, Deutsche Bank, i2 Technologies, Detroit Edison, Triton Container, and Susquehanna Partners. Founded in 1995, Secant Technologies is headquartered in Cleveland, Ohio. More information is available at http://www.secant.com .

============================================================